ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.
|Articles|February 3, 2021
Pfizer to Partner with Imcyse for Potential Rheumatoid Arthritis Treatment
Author(s)BioPharm International Editors
The companies have entered into a research collaboration and license agreement for the potential treatment of rheumatoid arthritis via Imcyse’s RA program based on its Imotope technology.
Advertisement
Pfizer and Imcyse, a Belgium-based clinical-stage biopharmaceutical company, announced on Feb. 3, 2021 that they have entered into a research collaboration and license agreement for the potential treatment of rheumatoid arthritis (RA) via Imcyse’s RA program based on its Imotope technology.
Under the terms of the agreement, Imcyse will receive an undisclosed upfront payment and will receive up to $180 million in milestone payments, Imcyse said in a company press release. Pfizer will be responsible for the clinical development and commercialization activities for the program.
“This license agreement constitutes a great endorsement and a sign of confidence in our Imotope technology platform from one of the leading pharmaceutical companies in the world. We are excited to expand our successful collaboration to develop Imotopes for RA, a prevalent autoimmune disorder,” said Denis Bedoret, Imcyse CEO, in the press release. “It is our ultimate goal to develop curative treatments for autoimmune disorders for the benefit of patients worldwide. For diseases such as RA, this can be best accomplished with the help of partners such as Pfizer.”
“Pfizer is committed to addressing the needs of patients in [r]heumatology, and the Imcyse technology platform offers a unique scientific approach that we look forward to exploring further,” added Mike Vincent, chief scientific officer, Pfizer Inflammation and Immunology, in the press release.
Source:
Advertisement
Related to this article
Beam’s base-edited cell therapy met its primary endpoint in the BEACON trial, and a U.S. biologics license application is planned as early as year-end.
AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.
Merck's GLP-1/glucagon co-agonist raised MASH resolution versus placebo at 52 weeks, but fibrosis and dose-response questions remain.
argenx's acquisition of Unnatural Products adds macrocyclic peptides that could yield oral or long-acting treatments for immune-mediated diseases.
UCB will use Cradle’s AI-driven protein design platform in selected discovery projects, from hit generation through preclinical readiness, expanding its digital antibody engineering program.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5